Food processing and nutrition company ADM has partnered with Qingdao Vland Biotech Group Co., Ltd. (Vland) to expand its human probiotics offering in China and better serve the demand of the nutrient supplements in the region, according to a press release.
“Vland is quite excited to partner with ADM to explore the promising market of human probiotics,” Aron Chen CEO of Vland, said in the press release. “We believe this strong partnership between Vland and ADM – powered by the technology, brand and sales channels of both parties – will be perfectly positioned to expand production and meet demand for high-quality human probiotics in China and for global customers.”
The companies have partnered to bring together expertise and resources to better manufacture and sell human probiotics using a wide-range set of technology, production and commercial tools and strong preclinical design model.
Subject to regulatory approval, the new joint venture is projected to launch in early 2022.
“We’re excited to partner with Vland to help meet the needs of consumers who are becoming increasingly aware of the strong linkage between health of the gut microbiome and their overall health,” Vince Macciocchi, president of ADM’s nutrition business, said in the press release. “Retail demand for probiotics in China is estimated to be $1 billion in 2022, with annual growth of more than 9 percent, and we believe this new venture – powered by the expertise and experience of both ADM and Vland – is perfectly positioned to play a leading role in meeting that demand.”
The probiotics market in China is predicted to be worth $1 billion by next year, a number projected to increase after figures saw an annual rate growth of 9%, according to the release.